Preemptive treatment with voriconazole in lung transplant recipients

C F Neoh1, G I Snell, B Levvey

  • 1Centre for Medicine Use and Safety, Monash University, Melbourne, Australia.

Abstract

Insights

Voriconazole preemptive treatment for lung transplant recipients showed a low incidence of invasive fungal infection (IFI) and IFI-related mortality. This study highlights voriconazole

Area of Science:

  • Medical Science
  • Pharmacology
  • Transplant Surgery

Background:

  • Invasive fungal infections (IFIs) pose a significant mortality risk for lung transplant (LTx) recipients.
  • Limited data exist on the efficacy of voriconazole for preemptive treatment in this vulnerable patient population.
  • Post-lung transplant colonization requires effective management strategies to prevent invasive disease.

Purpose of the Study:

  • To evaluate the efficacy and safety of voriconazole as a preemptive treatment for fungal colonization after lung transplantation.
  • To assess the incidence of invasive fungal infection (IFI) and mortality rates in lung transplant recipients receiving voriconazole prophylaxis.

Main Methods:

  • Retrospective cohort study of 62 adult lung transplant recipients receiving voriconazole prophylaxis.
  • Voriconazole was administered as preemptive treatment for post-transplant colonization.
  • Outcomes including IFI, colonization clearance, and mortality were assessed at 6 and 12 months.

Main Results:

  • A low incidence of IFI (1.6%) was observed at 6 months post-therapy.
  • Aspergillus fumigatus was the most common colonizing pathogen (75.8%).
  • Hepatotoxicity occurred in 16.1% of patients; diabetes and chronic rejection were associated with adverse outcomes.

Conclusions:

  • Voriconazole preemptive treatment demonstrates a low incidence of invasive fungal infection and associated mortality in lung transplant recipients.
  • The findings support the use of voriconazole for preemptive management of fungal colonization post-lung transplantation.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...